Pharmacopsychiatry
DOI: 10.1055/a-1252-2942
Original Paper

Subtypes of Clinical High Risk for Psychosis that Predict Antipsychotic Effectiveness in Long-Term Remission

1  Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai
,
JunJie Wang+
2  Institute of Mental Health, The Affiliated Guangji Hospital of Soochow University, Soochow University, Suzhou
,
LiHua Xu
1  Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai
,
YanYan Wei
1  Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai
,
XiaoChen Tang
1  Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai
,
YeGang Hu
1  Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai
,
HuiRu Cui
1  Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai
,
YingYing Tang
1  Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai
,
Li Hui
2  Institute of Mental Health, The Affiliated Guangji Hospital of Soochow University, Soochow University, Suzhou
,
ChunBo Li
1  Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai
,
JiJun Wang
1  Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Key Laboratory of Psychotic Disorders, Shanghai
3  Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai
4  Brain Science and Technology Research Center, Shanghai Jiao Tong University, Shanghai
› Author Affiliations
Funding: This study was supported by the Ministry of Science and Technology of China, National Key R&D Program of China (2016YFC1306800), National Natural Science Foundation of China (81671329, 81671332, 81901832), Shanghai Key Laboratory of Psychotic Disorders (13dz2260500), Science and Technology Commission of Shanghai Municipality (No.2018SHZDZX01, 19ZR1477800, 19ZR1445200, 19441907800, 17411953100, 19410710800, 19411969100, 20ZR1448600), Shanghai Clinical Research Center for Mental Health (19MC1911100), and Clinical Research Center at Shanghai Mental Health Center (CRC2018ZD01, CRC2018ZD04, and CRC2018YB01).

Abstract

Introduction In a previous report, we used canonical correlation analysis to classify individuals with clinical high risk (CHR) of psychosis into the 3 subtypes: subtype-1, characterized by extensive negative symptoms and cognitive deficits, appeared to have the highest risk for conversion to psychosis; subtype-2, characterized by thought and behavioral disorganization, with moderate cognitive impairment; subtype-3, characterized by the mildest symptoms and cognitive deficits. The present study attempted to identify these subtypes’ response to antipsychotic (AP) treatment.

Methods A total of 289 individuals with CHR were identified and followed up for 2 years. Individuals with CHR were classified by subtype. Use of APs was examined at 2-month, 1-year, and 2-year follow-up interviews that inquired after the subjects’ medication history since the first visit. The main outcome was remission, determined according to global assessment of function (GAF) score (i. e., functional outcome) and SIPS positive symptom score (symptomatic outcome) at the follow-up points.

Results Among the 289 individuals with CHR included in the current analysis, 223 (77.2%) were treated using APs for at least 2 weeks during the follow-up period. Individuals with CHR tended to show significant improvement in both symptoms and function after 2 years, but subtypes exhibited significantly different trajectories. Subtype status can predict AP treatment outcome in terms of remission. The likelihood of remission differed significantly among the subtype groups. The remission rates for individuals with subtypes 1–3 treated using AP were 13.5%, 36.1%, and 67.0%, respectively.

Discussion These subtypes may be of clinical value in AP treatment decision-making in the CHR population.

+ The author shares first authorship.


Supplementary Material



Publication History

Received: 06 July 2020
Received: 20 August 2020

Accepted: 21 August 2020

Publication Date:
12 October 2020 (online)

© 2020. Thieme. All rights reserved.

© Georg Thieme Verlag KG
Stuttgart · New York